NCT03122496

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.

Conditions

• Metastatic Anaplastic Thyroid Cancer

Interventions

Type	Name	Description
DRUG	durvalumab	Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
DRUG	tremelimumab	Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
RADIATION	Stereotactic Body Radiotherapy (SBRT)	SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab

Timeline

• Start date: 2017-04-25
• Primary completion: 2022-06-03
• Completion: 2022-06-03
• First posted: 2017-04-20
• Last updated: 2022-06-08

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study